Atezolizumab (MPDL3280A) |
رقم الكتالوجGC32704
One-Click Copy Product Info
|
أتيزوليزوماب (MPDL3280A) هو أحد الأجسام المضادة المونوكلونية الإنسانية المحددة التي تستهدف بروتين PD-L1 والتي تستخدم في البحث عن مرض السرطان.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1380723-44-3
Sample solution is provided at 25 µL, 10mM.
Atezolizumab (MPDL3280A) is an FcγR binding-deficient, fully humanized IgG1 mAb that specifically targets PD-L1[1]. Atezolizumab blocks binding of PD-L1 to receptors PD-1 and B7-1, thereby restoring anti-cancer T-cell activity and reinvigorating suppressed immune cells[2]. Atezolizumab has been widely used in cancer research to reduce immunosuppressive signals in the tumor microenvironment and enhance the migration of antigen-specific T cells[3].
In vitro, Atezolizumab treatment for 24h significantly inhibited the viability of HOS and 143B cells, with IC50 values of approximately 15μg/ml and 19μg/ml, respectively[4]. 0.5µg/ml of Atezolizumab treatment for 5 days down-regulated the activities of NF-κB, Akt and CD40 signaling pathways in MDA-MB-231 cells and promoted cell apoptosis[5]. Treatment with 800µg/ml Atezolizumab for 48 hours caused cytotoxicity in human liver cells, increased the release level of lactate dehydrogenase (LDH), and upregulated the expression of phosphorylated RIP3 and MLKL[6].
In vivo, Atezolizumab treatment via intraperitoneal injection at a dose of 10mg/kg, three times a week for 10 days, markedly restrained tumor growth in the MC38-hPD-L1 xenograft mouse model, without affecting the body weight[7]. Intraperitoneal injection of Atezolizumab at a dose of 100μg twice within 4 days reduced endotoxin levels and intestinal mucosal permeability, and improved the survival rate of septic mice[8].
References:
[1] Inman B A, Longo T A, Ramalingam S, et al. Atezolizumab: a PD-L1–blocking antibody for bladder cancer[J]. Clinical Cancer Research, 2017, 23(8): 1886-1890.
[2] Balar A V, Galsky M D, Rosenberg J E, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial[J]. The Lancet, 2017, 389(10064): 67-76.
[3] Wallin J J, Bendell J C, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma[J]. Nature communications, 2016, 7(1): 12624.
[4] Liu Z, Wang H, Hu C, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma[J]. Cell death & disease, 2021, 12(2): 164.
[5] Saleh R, Taha R Z, Sasidharan Nair V, et al. PD-L1 blockade by atezolizumab downregulates signaling pathways associated with tumor growth, metastasis, and hypoxia in human triple negative breast cancer[J]. Cancers, 2019, 11(8): 1050.
[6] Endo Y, Winarski K L, Sajib M S, et al. Atezolizumab induces necroptosis and contributes to hepatotoxicity of human hepatocytes[J]. International Journal of Molecular Sciences, 2023, 24(14): 11694.
[7] Acúrcio R C, Pozzi S, Carreira B, et al. Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment[J]. Journal for immunotherapy of cancer, 2022, 10(7): e004695.
[8] Chen J, Chen R, Huang S, et al. Atezolizumab alleviates the immunosuppression induced by PD‑L1‑positive neutrophils and improves the survival of mice during sepsis[J]. Molecular Medicine Reports, 2021, 23(2): 1-1.
| Cell experiment [1]: | |
|
Cell lines |
143B cells |
|
Preparation Method |
143B cells were cultured in high-glucose RPMI-1640 medium, supplemented 10% heat-inactivated fetal bovine serum, and 1% penicillin-streptomycin at 37°C in an incubator with 5% CO2. Cells were seeded in a 96-well plate at a density of 5×103 cells/well overnight. Cells were treated with different concentrations of Atezolizumab (0, 2.5, 5, 10, 20, and 40μg/ml), after 24h, cell viability was measured. |
|
Reaction Conditions |
0, 2.5, 5, 10, 20, and 40μg/ml; 24h |
|
Applications |
Atezolizumab treatment reduced cell viability of 143B cells in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
Male C57BL/6N-Pdcd1tm1(huPDCD1-ICP11)Geno mice |
|
Preparation Method |
Male C57BL/6N-Pdcd1tm1(huPDCD1-ICP11)Geno mice were bred with the appropriate temperature and humidity under a 12h light and darkness cycle, and food and water were readily available. Mice were implanted with 1×106 MC38 cells expressing humanized PD-L1 (MC38-hPD-L1) subcutaneously in the right flank. Twelve days later, when tumor volumes reached 60mm3 (40-110mm3) as measured by digital caliper, mice were randomized into the three treatment groups (n=6 per group). Atezolizumab was administered via i.p. injection at 10mg/kg three times per week between study days 12 and 22. The tumor size and body weight were measured every 3 days. |
|
Dosage form |
10mg/kg; three times per week; 10 days; i.p. |
|
Applications |
Atezolizumab administration inhibited tumor growth in mice with MC38-hPD-L1 xenografts, without affecting body weight. |
References: [1] Liu Z, Wang H, Hu C, et al. Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma[J]. Cell death & disease, 2021, 12(2): 164. [2] Acúrcio R C, Pozzi S, Carreira B, et al. Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment[J]. Journal for immunotherapy of cancer, 2022, 10(7): e004695. | |
| Cas No. | 1380723-44-3 | SDF | |
| Canonical SMILES | [Atezolizumab] | ||
| Formula | M.Wt | 144590.5 | |
| الذوبان | Storage | Store at -80°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 6.9 μL | 34.6 μL | 69.2 μL |
| 5 mM | 1.4 μL | 6.9 μL | 13.8 μL |
| 10 mM | 0.7 μL | 3.5 μL | 6.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)